Findings demonstrate improved liver lipid handling in steatotic liver disease, suggesting therapeutics target endocannabinoid system mechanisms.
These findings identify a novel, endocannabinoid system-independent mechanism by which CBD and CBG enhance hepatic energy buffering and lysosomal function, contributing to improved liver lipid handling and supporting phytocannabinoids as promising MASLD therapeutics.
No takes yet. Share an insight, caveat, or question.
Kočvarová et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: